We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Tool Facilitates Study of Mitochondrial DNA Variation

By LabMedica International staff writers
Posted on 17 Mar 2015
A new tool has been developed that enables researchers to study mitochondrial heteroplasmy and which will aid them in achieving better understanding of its impact on health and disease.

Investigators at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) described their "Mseek" technology in a paper published in the February 27, 2015, issue of the journal Nucleic Acids Research.

Heteroplasmy is the presence of a mixture of more than one type of an organellar genome (mitochondrial DNA (mtDNA) or plastid DNA) within a cell or individual. More...
It is a factor for the severity of mitochondrial diseases. Since most eukaryotic cells contain many hundreds of mitochondria with hundreds of copies of mtDNA, it is possible and indeed very frequent for mutations to affect only some mitochondria while others are unaffected. Heteroplasmy can be beneficial rather than detrimental insofar as centenarians show a higher than average degree of heteroplasmy.

Study of mitochondrial heteroplasmy has been complicated by the relatively small amount of mtDNA in each cell (less than 1% of the total DNA) and the intercellular variability of mtDNA content. To counter these problems, the Mt. Sinai investigators developed Mseek, which combines an enzymatic technique that purifies mitochondrial DNA by deleting the nuclear DNA and an advanced deep DNA sequencing procedure for analysis of the pure mitochondrial DNA.

The investigators reported that Mseek yielded high purity (greater than 90%) mtDNA, and that its ability to detect rare variants was limited only by sequencing depth, providing unprecedented sensitivity and specificity. Using Mseek, they confirmed the ubiquity of heteroplasmy by analyzing mtDNA from a diverse set of cell lines and human samples. Applying Mseek to colonies derived from single cells, they found that heteroplasmy was stably maintained in individual daughter cells over multiple cell divisions.

“Researchers have struggled to sequence mtDNA accurately and in a cost effective manner,” said senior author Dr. Ravi Sachidanandam, assistant professor of oncological sciences at the Icahn School of Medicine at Mount Sinai. “The technique we have developed will allow us to identify dysfunction within mitochondria and makes mtDNA a useful biomarker as well as a potential therapeutic target in cancer and many inherited diseases. We hypothesized that heteroplasmy could be stabilized by intercellular exchange of mtDNA. Our results demonstrated the exchange of mtDNA is possible and heteroplasmy can be maintained stably through this mechanism. This technique could provide a novel platform to investigate features of heteroplasmy in normal and diseased state and in the future, the exchange mechanism could be used as a treatment that targets bad mtDNA and exchanges it with good mtDNA.”

Related Links:

Icahn School of Medicine at Mount Sinai



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Clinical Informatics Platform
CLARION™
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.